Last mentioned: Mar 16, 2026
Application Refusal
FDA senior regulator Vinay Prasad issues a formal refusal to review the flu vaccine application.
Grants Rescinded
White House rescinds hundreds of millions in mRNA research grants by year-end.
Workaround Supported
Regulators appear to support Moderna's plan to use data from a smaller trial to address dosage concerns.
Collaboration Begins
FDA begins working closely with Moderna on its flu vaccine trial design.
Moderna faces a significant regulatory setback as the FDA refuses to review its new flu vaccine, citing trial design flaws despite previous guidance. This shift reflects a broader, politically charged environment that threatens to destabilize the venture-backed biotech ecosystem.
This page surfaces every story mentioning Vinay Prasad across our startup coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running startup beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Vinay Prasad was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |